Next Article in Journal
Applicability of Supraclavicular Oxygenated and Total Hemoglobin Evaluated by Near-Infrared Time-Resolved Spectroscopy as Indicators of Brown Adipose Tissue Density in Humans
Next Article in Special Issue
Mechanism of CK2.3, a Novel Mimetic Peptide of Bone Morphogenetic Protein Receptor Type IA, Mediated Osteogenesis
Previous Article in Journal
Molecular Signature of Prospero Homeobox 1 (PROX1) in Follicular Thyroid Carcinoma Cells
Previous Article in Special Issue
The Role of Macrophage in the Pathogenesis of Osteoporosis
 
 
Review

Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions

by 1,2, 1 and 3,4,*
1
Department of Physical Medicine and Rehabilitation, Mackay Memorial Hospital, Taipei 10449, Taiwan
2
Department of Mechanical Engineering, National Chiao-Tung University, Hsinchu 30010, Taiwan
3
Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 23142, Taiwan
4
School of Medicine, Tzu-Chi University, Hualien 97004, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(9), 2213; https://doi.org/10.3390/ijms20092213
Received: 29 March 2019 / Revised: 27 April 2019 / Accepted: 4 May 2019 / Published: 6 May 2019
(This article belongs to the Special Issue Osteoporosis: From Molecular Mechanisms to Therapies)
Osteoporosis is a major concern all over the world. With aging, a gradual loss of bone mass results in osteopenia and osteoporosis. Heritable factors account for 60–80% of optimal bone mineralization. Modifiable factors, such as weight-bearing exercise, nutrition, body mass, and hormonal milieu, play an important role in the development of osteopenia and osteoporosis in adulthood. Currently, anti-resorptive agents, including estrogen, bisphosphonates, and selective estrogen receptor modulators (SERMs), are the drugs of choice for osteoporosis. Other treatments include parathyroid hormone (PTH) as well as the nutritional support of calcium and vitamin D. New treatments such as tissue-selective estrogen receptor complexes (TSECs) are currently in use too. This review, which is based on a systematic appraisal of the current literature, provides current molecular and genetic opinions on osteoporosis and its medical treatment. It offers evidence-based information to help researchers and clinicians with osteoporosis assessment. However, many issues regarding osteoporosis and its treatment remain unknown or controversial and warrant future investigation. View Full-Text
Keywords: osteoporosis; anti-resorptive drugs; molecular pathway; genetics osteoporosis; anti-resorptive drugs; molecular pathway; genetics
Show Figures

Graphical abstract

MDPI and ACS Style

Chen, L.-R.; Ko, N.-Y.; Chen, K.-H. Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions. Int. J. Mol. Sci. 2019, 20, 2213. https://doi.org/10.3390/ijms20092213

AMA Style

Chen L-R, Ko N-Y, Chen K-H. Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions. International Journal of Molecular Sciences. 2019; 20(9):2213. https://doi.org/10.3390/ijms20092213

Chicago/Turabian Style

Chen, Li-Ru, Nai-Yu Ko, and Kuo-Hu Chen. 2019. "Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions" International Journal of Molecular Sciences 20, no. 9: 2213. https://doi.org/10.3390/ijms20092213

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop